<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289236</url>
  </required_header>
  <id_info>
    <org_study_id>SAV-MD-02</org_study_id>
    <nct_id>NCT01289236</nct_id>
  </id_info>
  <brief_title>&quot;MILNACIPRAN&quot; in Subjects With Chronic Shoulder Pain</brief_title>
  <official_title>An Exploratory, Randomized, Single Blinded, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of &quot;MILNACIPRAN&quot; in Subjects With Chronic Shoulder Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valera Bussell</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Delray Research Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of multiple doses of
      &quot;Milnacipran&quot; to a placebo dose in subjects with Chronic Shoulder Pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 weeks. It is planned that this study will be conducted at a single site and will enroll
      approximately 40 subjects over 2-4 months. At the end of the 12-week dosing period, the study
      drug will be discontinued and all subjects in the treatment groups and control group will be
      followed for an additional 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint will be the reduction in the mean VAS for chronic shoulder pain</measure>
    <time_frame>Week 12</time_frame>
    <description>The primary efficacy endpoint will be the reduction in the mean VAS (Visual Analog Scale) for chronic shoulder pain at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the PGIC</measure>
    <time_frame>Week 12</time_frame>
    <description>Overall improvement in the PGIC (Patient Global Impression of Change) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An improvement in the SPADI score</measure>
    <time_frame>Week 12</time_frame>
    <description>Improvement in the SPADI (Shoulder Pain and Disability Index) score at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the SF-36 Health Questionnaire</measure>
    <time_frame>Week 12</time_frame>
    <description>Improvement in the SF-36 (Short Form-36) Health Questionnaire at Week 12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID (twice daily, approximately 12 hours apart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>milnacipran 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>milnacipran 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>milnacipran</intervention_name>
    <description>1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period</description>
    <arm_group_label>milnacipran 100 mg</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.</description>
    <arm_group_label>milnacipran 200 mg</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males, postmenopausal/ sterile females or females using reliable contraceptives who
             are &gt;25 years of age.

          2. Chronic shoulder pain in at least one shoulder for &gt; 3 months (If both shoulders are
             painful, the investigator will choose the most painful shoulder for evaluation during
             the study) If both are equally painful, the investigator will choose the shoulder for
             evaluation.

          3. History of shoulder or proximal arm pain due to bursitis, osteoarthritis of the
             shoulder, impingement or rotator cuff tear.

          4. Subjects who give their written informed consent.

          5. Subjects who at screening are not on chronic analgesic/anti-inflammatory medication
             and have a VAS pain score of &gt; 40mm and &lt; 90mm or subjects who are on chronic
             analgesic/anti-inflammatory medication at screening and have a VAS pain score of &gt;
             30mm and &lt; 90mm, indicating a lack of adequate and sustained response to current
             therapy.

          6. At baseline, after all analgesic/anti-inflammatory medication has been discontinued
             for 2 weeks (including withdrawal from acetaminophen rescue medication for 24 hours
             prior to screening) should have a VAS pain score of &gt; 40mm and &lt; 90mm.

          7. Subjects who are willing to discontinue all NSAIDs or other analgesic medication taken
             for their shoulder pain with the exception of acetaminophen 500-1000mg (1-2 tablets)
             q.i.d., p.r.n. (maximum 8 tablets or 4 grams per day. Subjects must be willing to use
             only acetaminophen as a rescue pain medication for the shoulder pain. All analgesic
             medications must be stopped at least 2 weeks prior to the baseline visit and all
             acetaminophen must be discontinued at least 24 hours prior to the baseline visit.
             Subjects must be willing to abstain from any peri-articular injections for the
             shoulder during the course of the trial.

          8. Subjects who have an x-ray at screening or MRI within 6 months prior to screening.

        Exclusion Criteria:

          1. Women of childbearing potential may not be entered if:

             Their pregnancy tests (urine) are positive They are nursing They do not use or agree
             to use an effective method of contraception until all follow-up procedures are
             complete. (Acceptable methods of contraception are oral, injectable, implanted
             contraceptive agent, abstinence or an intra-uterine device with a failure rate of &lt; 1%

          2. Participation in another experimental drug/device study within the past 30 days.

          3. Acute infection of the study joint

          4. History of adverse reaction or allergy to milnacipran or acetaminophen

          5. Shoulder pain due to an injury for which litigation is planned or pending.

          6. Any cervical spine disease that in the opinion of the investigator could confound
             assessments during the study.

          7. Use of any oral corticosteroid during the past 30 days or peri-articular
             corticosteroid injection during the past 1 month.

          8. Subjects with shoulder x-ray findings of fractures or avascular necrosis.

          9. Subjects with any inter-current disease or condition that may interfere with the free
             use or evaluation of the affected shoulder for the duration of their participation in
             the study (severe congenital defects, weight bearing use of the shoulder due to
             crutches, walkers, canes etc.)

         10. Subjects with history of alcohol or drug abuse within the past 5 years.

         11. Subjects who have a compromised mental capacity or who may be unable to legally
             comprehend the details and nature of the study.

         12. In the opinion of the investigator, a clinically significant abnormal lab results or
             history of disease that may place the subject at a health risk or compromise the study
             data or affect the subject's ability to complete the study.

         13. Subjects who in the opinion of the investigator are unlikely to adhere to the study
             protocol or to complete the study as planned.

         14. Subject has a chronic pain condition (chronic low back pain, chronic headache,
             fibromyalgia, chronic osteoarthritis, chronic rheumatoid arthritis etc.) that could
             confound the shoulder pain response to the study medication(in the opinion of the
             investigator)

         15. Subject is using and is not willing to discontinue opioids, topical counterirritants
             (eg methylsalicylate or capsaicin) or the use of orthopedic devices for the study
             shoulder.

         16. Significant liver impairment (defined as liver enzymes elevated more than three times
             the upper limit of normal) or significant renal impairment (defined as a serum
             creatinine level greater than twice the upper limit of normal.

         17. Uncontrolled hypertension, history of stroke or transient ischemic attack within 6
             months of enrollment, epilepsy, history of malignant neoplastic disease that is active
             (basal cell carcinoma of the skin is permitted), active infectious disease.

         18. Subjects who have a history of uncontrolled Narrow Angle Glaucoma

         19. Subjects who test positive for illegal or prohibited substances at Screening as
             demonstrated by a positive urine test or based on the Investigator's judgment.

         20. Subjects who have active peptic ulcer disease, a history of inflammatory bowel disease
             or celiac sprue.

         21. Subjects who have pulmonary dysfunction or severe chronic obstructive pulmonary
             disease that in the Investigator's opinion could interfere with study participation
             and completion.

         22. Subjects who have unstable endocrine disease, including unstable diabetes or thyroid
             disease. Subjects with endocrine disorders that have been stable for the preceding 3
             months will be permitted to enroll.

         23. Male subjects with prostatic enlargement or other genitourinary disorders that put
             them at potentially significant risk for dysuria and/or urinary retention while taking
             agents with noradrenaline-reuptake inhibition properties (Entry permitted at
             Investigator's discretion)

         24. Subjects who must participate in Physical Therapy during the course of their
             participation, unless stable in the opinion of the investigator.

         25. Subjects with shoulder pain or other referred pain that does not originate from the
             shoulder.

         26. Subjects who are taking SNRIs such as: Cymbalta

         27. Subjects who are taking Lyrica or Neurontin

         28. Subjects with cervical radiculopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe A Saxe, MD,FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Delray Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Delray Research Associates</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Delray Research Associates</investigator_affiliation>
    <investigator_full_name>Valera Bussell</investigator_full_name>
    <investigator_title>Sponsor Representative</investigator_title>
  </responsible_party>
  <keyword>Shoulder Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

